From Barchart:

Novavax Inc. (NVAX) stock is down, but some analysts believe the pessimism may be overdone, leading to a potential rebound. The company’s COVID-19 vaccine is still under review by the FDA, with potential for approval in the near future. With promising vaccine data, NVAX stock could see an uptick in the coming months.



Read more: Why Novavax (NVAX) Just Might Surprise the Bears